Detection of Cannabis Impairment With an Eye Tracker

• Status: Completed
• Trial end date: 2019-11-15
• Target enrollment: 0
• Participant gender: All

Summary

Cannabis is one of the widely used psychoactive substances in the world. With increasing legalization, the prevalence of driving under the influence of cannabis will undoubtedly rise. At present, roadside detection of cannabis intoxication is largely dependent on drug recognition experts who rely on changes in eye movements when impaired. In this regard, use of eye trackers can help to detect impairment in drivers. The purpose of the present study is to determine the feasibility of the use of eye trackers in detecting impairment in participants who smoked a cannabis cigarette.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centre for Addiction and Mental Health

Criteria

Inclusion Criteria:

• Weekly use of cannabis (1 to 4 days per week) confirmed by urine point-of-care testing;

• 19-26 years of age;

• holds a class G or G2 Ontario driver's licence (or equivalent from another jurisdiction) for at least 12 months;

• Willing to abstain from using alcohol for 48 hours and cannabis for 72 hours prior to the study session;

• Willing to abstain from all other drugs not prescribed for medical purposes for the duration of the study;

• Provides written and informed consent.

Exclusion Criteria:

• Urine toxicology screens negative for cannabis upon eligibility assessment;

• Diagnosis of severe medical or psychiatric conditions;

• Females: Pregnancy or breastfeeding;

• Meets criteria for Alcohol or Substance Dependence (current or lifetime) (DSM-IV);

• Is a regular user of medications that affect brain function (i.e., antidepressants, benzodiazepines, stimulants);

• First-degree relative diagnosed with schizophrenia.